Key facts
- Notable investors include Hana Capital, IGIS Asset Management, New Flight.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Monit Cell
- ·The full record, as it builds
Funding rounds
No funding rounds for Monit Cell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Monit Cell
Developer of a stem cell therapy designed to treat intractable diseases. The company's platform gives cell banking-based advanced complex regenerative treatment by utilizing human-derived fat, enabling patients to lead a healthier and more beautiful life.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 16
- Website
- monitcell.oopy.io/
- Ownership
- Privately Held (backing)
Monit Cell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Monit Cell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Monit Cell in its N-PORT filings yet. We sweep new filings monthly.